" class="no-js "lang="en-US"> Anthony Hall - Medtech Alert
Saturday, August 23, 2025
Anthony Hall

Anthony Hall

About Anthony Hall

An experienced pharmaceutical physician with knowledge spanning a broad range of disciplines and therapy areas. Having founded and built my own successful company, I have a demonstrated ability to lead, inspire and motivate, together with keen strategic vision and commercial acumen.

From 2010 – 2014, I worked as a consultant exclusively on Orphan drugs and became heavily involved with all facets of the rare diseases community, regularly speaking at conferences. I have built trusted relationships with stakeholders at many different levels, including patient groups, key opinion leaders and academics. I have gained significant experience in drug development for orphan drugs, from understanding the special regulatory requirements applicable for orphan drugs to designing the clinical programs to meet them.

I am very interested in clinical endpoint development, including surrogate endpoints and in innovative drug development pathways, such as adaptive licensing with the involvement of all stakeholders, including payers at an early stage.

I graduated from King’s College London with first class honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital, London.

Specialties: Rare diseases;
Orphan Drugs;
Clinical Development planning;
Medical & regulatory drug development expertise;
Company start-up expertise

Related Story

Healx Receives IND and Orphan Drug Designation for Fragile X Clinical Trial

October 20 2021

Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, is proud […]